A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res. 2004 Apr; 28(4):353-7.